I have a letter from Donna Shalala, the Secretary of HHS, and I quote from the letter that has been distributed throughout the Senate this afternoon. Secretary Shalala says: It will be nearly impossible to meet the substantial investment requirement under the Hatch substitute. She concludes saying: It would be virtually impossible for a manufacturer to obtain FDA approval for a generic drug product during this transition period.
William Pryor: “I have a letter from Donna Shalala, the Secretary of HHS, and I quote from the letter that has been distributed…”
On the recordJune 27, 1996
Said by
William Pryor
Source
govinfo.govEditor's note · Context
Discussing concerns about the Hatch substitute related to FDA approval for generic drugs.
Share
More from William Pryor
Mar 6, 2008
Yes, it is. Compliance with proposition 65's warning requirements would only complement the CPSC Reform Act.
Mar 4, 2008
let me start our conversation this afternoon about the consumer product safety bill with a chart. I will come back to it in a few minutes, but as the camera focuses on this chart, these are the toys that were recalled in the last year. You…
Feb 15, 2007
I wish to introduce two communications bills. First, I am introducing the Child Safe Viewing Act, a bill to develop the next generation of parental control technology. Last year, following several hearings and forums on decency, I…